Economic evaluation of recombinant human copper zinc superoxide dismutase administered at birth to premature infants

Journal of Perinatology

Volumn 29, Issue 5, 2009, Pages 364-371

  McBride, J A ^a   Parad, R B ^a,b   Davis, J M ^c   Zheng, Z ^d   Zupancic, J A F ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; OXYGEN; PLACEBO; RECOMBINANT HUMAN COPPER ZINC SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ARTICLE; BIRTH WEIGHT; CHILDBIRTH; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; GESTATIONAL AGE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEWBORN; POPULATION RESEARCH; PREMATURITY; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

BRONCHOPULMONARY DYSPLASIA; CONFIDENCE INTERVALS; COST SAVINGS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HOSPITAL COSTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SUPEROXIDE DISMUTASE;

EID: 67349171043     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2008.225     Document Type: Article

References (24)

1. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 2006; 367: 1421-1431.
2. Waitzman NJ, Rogowski J. Societal costs of preterm birth. In: Behrman R, Stith-Butler A (eds). Preterm Birth: Causes, Consequences and Prevention. The National Academic Press: Washington, D.C., 2006, pp 398-429.
3. Rogowski J. Cost-effectiveness of care for very low birth weight infants. Pediatrics 1998; 102: 35-43.
4. Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ et al. Rehospitalization in the first year of life among infants with bronchopulmonary dysplasia. J Pediatr 2004; 144: 799-803.
5. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003; 111: 469-476.
6. Center for Medicare and Medicaid Services. Hospital Cost Report, Fiscal Years 1996. Current 2006 [updated 2006 April 12, 2006; cited]; Available from: http://www.cms.hhs.gov/CostReports/ 02_HospitalCostReport.asp.
7. Red Book: Pharmacy's Fundamental Reference. Thomson PDR: Montvale, NJ, 2006.
8. HCUP Kids' Inpatient Database (KID). Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality: Rockville, MD, 2003 [updated 2003; cited]; Available from: www.hcup-us.ahrq.gov/kidoverview.jsp.
9. RBRVS: What is it and how does it affect pediatrics? American Academy of Pediatrics 2007 [updated 2007; cited 2006 December 20, 2006]; Available from: http://practice.aap.org/content.aspx?aID=1652.
10. Consumer Price Index (Medical Care, all Urban Consumers, Northeast Urban) National Bureau of Labor Statistics 2006 [updated 2006; cited 2006 July 1]; Available from: http://www.bls.gov/cpi/.
11. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327-340.
12. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman and Hall/CRC: New York, 1993.
13. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ 2001; 10 779-787.
14. Petrou S, Bischof M, Bennett C, Elbourne D, Field D, McNally H. Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial. Pediatrics 2006; 117: 1640-1649.
15. Lorch SA, Cnaan A, Barnhart K. Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn. Pediatrics 2004; 114: 417-426.
16. Keren R, Helfand M, Homer C, McPhillips H, Lieu TA. Projected cost-effectiveness of statewide universal newborn hearing screening. Pediatrics 2002; 110: 855-864.
17. Backhouse ME, Mauskopf JA, Jones D, Wold DE, Schumacher R, Cotton R et al. Economic outcomes of colfosceril palmitate rescue therapy in infants weighing 1250 g or more with respiratory distress syndrome: results from a randomised trial. Pharmacoeconomics 1994; 6: 358-369.
18. Wang LY, Zhong Y, Wheeler L. Direct and indirect costs of asthma in school-age children. Prev Chronic Dis 2005; 2: A11.
19. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156: 787-793.
20. Parad R, Allred E, Rosenfeld W, Davis J, The North American rhSOD Study Group. Incidence and severity of retinopathy of prematurity (ROP) is reduced in extremely low gestational age (GA) newborns (ELGANS) treated with recombinant human Cu/Zn superoxide dismutase (rhSOD) [Abstract]. Pediatric Academic Societies. (http://www.pas-meeting.org/ 2009Baltimore/abstract_archives.asp) 2007; 8225: 6.
21. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405-415.
22. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Cost-Effectiveness in Health and Medicine. Oxford University Press: New York, 1996.
23. Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ et al. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr 2005; 146: 469-473.
24. O'Brien B. Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? Med Care 1996; 34: DS99-D108.